Protein / target

Killer cell immunoglobulin-like receptor 2DL3

Encoded byKIR2DL3P43628Homo sapiensSwiss-Prot

UniProt: P43628 Ensembl: ENSG00000243772 HGNC: HGNC:6331 NCBI Gene: 3804

Clinical-stage

Therapeutic maturity

Clinical candidates

Clinical trials

Antibody-tractable

Druggability

Advanced Clinical

Protein at a glance

Biological role

Transmembrane signaling receptor

Strongest disease association

Leukemia, Myeloid, Acute

Via encoding gene KIR2DL3 · Literature evidence · score 0.11

Therapeutic position

Clinically advancing target

Antibodies

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7).

View complete UniProt function annotation

Receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). Inhibits the activity of NK cells thus preventing cell lysis

Subcellular location

Cell membrane

Domains and Gene Ontology detail (11)

Domains & features

Ig-like C2-type 1Ig-like C2-type 2

Gene Ontology

Cmembrane
Cplasma membrane
Fantigen binding
Fidentical protein binding
Fimmune receptor activity
Fsignaling receptor activity
Ftransmembrane signaling receptor activity
Pimmune response
Pimmune response-inhibiting cell surface receptor signaling pathway

341 aa · 38 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGO

View supporting evidence

Immune signalling

·antigen binding
·immune response
·immune response-inhibiting cell surface receptor signaling pathway

View underlying pathways (1)

Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

lirilumab

Narrow target profilePhase 2Inhibitor

Killer cell immunoglobulin-like receptor 2DL3 inhibitor

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene KIR2DL3

Gene-level evidence surfaced through the gene KIR2DL3that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Leukemia, Myeloid, Acute

0.19Preliminary

Clinical evidence dominant · Open Targets 0.11

Multiple Myeloma

0.14Preliminary

Clinical evidence dominant · Open Targets 0.11

Myelodysplastic syndrome

0.13Preliminary

Clinical evidence dominant · Open Targets 0.09

Leukemia, Lymphocytic, Chronic, B-Cell

0.13Preliminary

Clinical evidence dominant · Open Targets 0.10

Prostatic Neoplasms

0.12Preliminary

Somatic mutation evidence dominant · Open Targets 0.11

View evidence synthesis (5)

Leukemia, Myeloid, AcutePreliminary

0.19

agreement 0.03–0.34

Clinical61%Literature39%

Open Targets aggregate 0.11 · 2 independent evidence families

Multiple MyelomaPreliminary

0.14

agreement 0.00–0.29

Clinical98%Literature2%

Open Targets aggregate 0.11 · 2 independent evidence families

Myelodysplastic syndromePreliminary

0.13

agreement 0.00–0.26

Clinical89%Literature9%RNA expression3%

Open Targets aggregate 0.09 · 3 independent evidence families

Leukemia, Lymphocytic, Chronic, B-CellPreliminary

0.13

agreement 0.00–0.28

Clinical89%Literature11%

Open Targets aggregate 0.10 · 2 independent evidence families

Prostatic NeoplasmsPreliminary

0.12

agreement 0.00–0.30

Somatic mutation100%

Open Targets aggregate 0.11 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Leukemia, Myeloid, Acute0.11

Prostatic Neoplasms0.11

Familial prostate cancer0.11

Multiple Myeloma0.11

Leukemia, Lymphocytic, Chronic, B-Cell0.10

Myelodysplastic syndrome0.09

Squamous Cell Carcinoma of Head and Neck0.08

Malaria, Cerebral0.07

Lupus Erythematosus, Systemic0.07

Drug development

2 compounds recorded · 2 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (2)

IPH-2101Phase 2

LIRILUMABPhase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Antibodies — Strong

Advanced Clinical and GO CC high conf support this modality.

View underlying tractability evidence (4)

AB · Advanced ClinicalAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and NeckPHASE2

ACTIVE_NOT_RECRUITING · via lirilumab · NCT03341936

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsPHASE1/PHASE2

RECRUITING · via lirilumab · NCT02813135

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)PHASE1/PHASE2

TERMINATED · via lirilumab · NCT03347123

Phase II Combination of Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)PHASE2

TERMINATED · via lirilumab · NCT02599649

View all trials (7)

Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)PHASE2

COMPLETED · via lirilumab · NCT02481297

An Open-Label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid LeukemiaPHASE2